{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:25:03Z","timestamp":1769077503854,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ygyno.2018.08.028","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T17:15:27Z","timestamp":1535476527000},"page":"82-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology"],"prefix":"10.1016","volume":"151","author":[{"given":"Ashwin","family":"Shinde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8311-9159","authenticated-orcid":false,"given":"Arya","family":"Amini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh","family":"Dellinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushil","family":"Beriwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.08.028_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0010","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s10552-010-9612-8","article-title":"Factors associated with type I and type II endometrial cancer","volume":"21","author":"Felix","year":"2010","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2018.08.028_bb0015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.08.028_bb0020","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2009.02.003","article-title":"Management of women with clear cell endometrial cancer","volume":"113","author":"Olawaiye","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/CCO.0b013e328349a45b","article-title":"Uterine carcinosarcoma","volume":"23","author":"Arend","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0030","series-title":"Uterine Neoplasms, Pract. Guidel. Oncol.","first-page":"1","author":"NCCN","year":"2018"},{"key":"10.1016\/j.ygyno.2018.08.028_bb0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ygyno.2014.12.034","article-title":"Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study","volume":"136","author":"Mahdi","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2012.12.026","article-title":"Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer","volume":"129","author":"Townamchai","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2012.03.011","article-title":"The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial Cancer","volume":"85","author":"Barney","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0055","series-title":"National Cancer Data Base: Participant User File Data Dictionary","author":"American College of Surgeons","year":"2017"},{"key":"10.1016\/j.ygyno.2018.08.028_bb0060","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0065","series-title":"ICD-O-3 Online","author":"International Classification of Diseases for Oncology","year":"2013"},{"key":"10.1016\/j.ygyno.2018.08.028_bb0070","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-10-20","article-title":"Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer","volume":"10","author":"Bellera","year":"2010","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0075","series-title":"GOG-249 Confirms Adjuvant Pelvic Radiation as Standard of Care for High-Risk, Early-Stage Endometrial Cancer","author":"ASTRO","year":"2017"},{"key":"10.1016\/j.ygyno.2018.08.028_bb0080","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2013.48.8023","article-title":"Long-term outcomes after pelvic radiation for early-stage endometrial cancer","volume":"31","author":"Onsrud","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0085","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/IGC.0000000000000926","article-title":"Impact of chemotherapy and radiotherapy on management of early stage clear cell and papillary serous carcinoma of the uterus","volume":"27","author":"Hong","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.08.028_bb0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ygyno.2017.01.010","article-title":"Stage I uterine carcinosarcoma: matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0095","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/IGC.0000000000000640","article-title":"Utilization and role of adjuvant radiotherapy and chemotherapy for uterine clear cell carcinoma","volume":"26","author":"Xu","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.08.028_bb0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2017.11.010","article-title":"Adjuvant therapy in patients with clear cell endometrial carcinoma: an analysis of the National Cancer Database","volume":"148","author":"Nieto","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.brachy.2017.09.011","article-title":"Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: a National Cancer Database analysis","volume":"17","author":"Stokes","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ygyno.2018.08.028_bb0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/COC.0000000000000065","article-title":"Adjuvant pelvic radiation therapy\u202f\u00b1\u202fvaginal brachytherapy in patients with high-risk stage I or stage II uterine papillary serous, clear cell, and high-grade Endometrioid carcinoma","volume":"39","author":"Nagar","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0115","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ygyno.2017.03.003","article-title":"Utility of radiation therapy for early-stage uterine papillary serous carcinoma","volume":"145","author":"Cham","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0120","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2016.27.e19","article-title":"The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone","volume":"27","author":"Mahdi","year":"2016","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0125","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ygyno.2014.02.021","article-title":"Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: A population-based analysis","volume":"133","author":"Garg","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0130","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ygyno.2013.10.010","article-title":"Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy","volume":"131","author":"Chang-Halpenny","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2018.03.002","article-title":"The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: a multi-institutional pooled analysis","author":"Qu","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.028_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/COC.0000000000000273","volume":"41","author":"Cahan","year":"2016","journal-title":"Am. J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818311594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818311594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T18:29:54Z","timestamp":1661884194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818311594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0090825818311594"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.028","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}